New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant Voyager’s wholly-owned Alzheimer’s disease franchise now includes clinical-stage anti-tau antibody VY7523 as well as gene therapies targeting tau, amyloid, and APOE LEXINGTON, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc.... Read More

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid... Read More

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled “Highly conserved brain vascular... Read More

Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ 2025 continue to support tau as next critical target in Alzheimer’s disease LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a... Read More

Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg Featured data also include anti-amyloid gene therapy for Alzheimer’s disease, as well as multiple presentations on Voyager’s continued enhancements to its highly BBB penetrant novel capsids LEXINGTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Voyager... Read More

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data LEXINGTON, Mass., March 31, 2025... Read More

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer’s patients expected H2 2026 LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc.... Read More

LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on... Read More

Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile - MAD study initiated in patients with early Alzheimer’s disease; initial tau PET imaging data expected in H2 2026 - LEXINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing... Read More

LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences: TD Cowen 45 th Annual Health Care Conference, in Boston, including a fireside chat at 1:50 p.m. ET on March 3, 2025 Stifel 2025 Virtual CNS Forum, including a fireside... Read More

Company to assess alternate payloads; no changes planned to novel capsid component Resulting shift of timeline and costs extends cash runway into mid-2027 All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced... Read More

LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25 th Annual Healthcare Life Sciences Conference at 2:40 p.m. ET on February 11, 2025. A webcast of the presentation will be available and may be accessed from the Investors section of... Read More

Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager’s IV-delivered, CNS-penetrant TRACER capsids LEXINGTON, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines,... Read More

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide support for use of an antibody to target tau in Alzheimer’s Continued partnership progress in Q3 2024 evidenced by new capsid license and new gene... Read More

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences: Truist Securities BioPharma Symposium, in New York City, including a panel discussion on Genetic Medicines at 1:45 p.m. ET on November 7, 2024 Guggenheim Inaugural... Read More

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on... Read More

LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences, Inc. has selected a development candidate in a gene therapy program for the potential treatment of an undisclosed neurological disease. The candidate leverages an... Read More

LEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE: NVS) has agreed to license a novel capsid generated from Voyager’s TRACER™ capsid discovery platform for use in a gene therapy program against an undisclosed rare neurologic disease target. This capsid license is being... Read More

LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such employee’s entering into... Read More

LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in multiple upcoming investor conferences: The Wells Fargo 2024 Healthcare Conference, in Boston, including a fireside chat at 1:30 p.m. ET on September 5, 2024 The Baird 2024 Global Healthcare Conference, in New... Read More

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET. A webcast of the presentation may be accessed from the Investors section... Read More

Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer’s disease Three CNS gene therapy programs on track for INDs in 2025 following development candidate nominations for GBA1 and FA programs and pre-IND meeting for SOD1 ALS development candidate Appointed strategic financial leader Nathan Jorgensen, Ph.D., as Chief Financial Officer... Read More

LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. To participate via telephone and join the call... Read More

LEXINGTON, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Eric Hall, Ph.D., M.B.A. that, among other things, provides for the grant to Dr. Hall of a non-qualified stock option and restricted stock units as an inducement material to Dr. Hall’s entering into employment with... Read More

LEXINGTON, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Nathan Jorgensen, Ph.D., M.B.A. that, among other things, provides for the grant to Dr. Jorgensen of a non-qualified stock option and restricted stock units as an inducement material to Dr. Jorgensen’s entering into... Read More

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024, at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024, at 7:00 a.m. ET.... Read More

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side... Read More

LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau antibody developed to inhibit the spread of pathological tau in Alzheimer’s disease. The objective of the randomized,... Read More

Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks Development candidates selected for Neurocrine-partnered GBA1 and Friedreich’s Ataxia gene therapy programs; potential for three gene therapies, including SOD1-ALS, to enter the clinic in 2025 Appointed neurology clinical development... Read More

Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding Preclinical safety and efficacy demonstrated in Alzheimer’s disease and ALS gene therapies; low IV doses provided broad CNS biodistribution and robust transduction of key cell types LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc.... Read More

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report first quarter 2024 financial and operating results after market close on Monday, May 13, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results. To... Read More

LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene therapy programs across 12 oral and poster presentations at the upcoming American Society of Gene & Cell Therapy’s (ASGCT) 27th... Read More

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The... Read More

LEXINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Toby Ferguson, M.D., Ph.D. that, among other things, provides for the grant to Dr. Ferguson of a non-qualified stock option and restricted stock units as an inducement material to Dr. Ferguson’s entering into... Read More

LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse... Read More

Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering Strong cash position and anticipated milestones/reimbursements provide runway into 2027, potentially enabling the generation of clinical data from multiple programs Lead development candidates selected in Friedreich’s ataxia gene therapy program in... Read More

LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the Friedreich’s ataxia (FA) program. The candidate combines a frataxin (FXN) gene replacement payload with an... Read More

LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 financial and operating results after market close on Wednesday, February 28, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating... Read More

Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) Data to be presented at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2024) LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR),... Read More

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Financial Officer Peter Pfreundschuh will present at the Oppenheimer Life Sciences Conference on February 14, 2024, at 11:20 a.m. ET. A webcast of the presentation may be accessed from the Investors section of Voyager’s website at... Read More

LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and, to investors who so choose in lieu of common stock, pre-funded warrants to purchase an aggregate of... Read More

LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof). All of the securities in the proposed offering are to be sold by the Company.... Read More

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024, at 9:45 a.m. PT (12:45 p.m. ET). A webcast of the presentation may be... Read More

Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy Voyager to receive up-front consideration of $100 million and is eligible to receive milestone payments and tiered royalties LEXINGTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic... Read More

LEXINGTON, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program. The Company anticipates filing an investigational new drug (IND)... Read More

GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing SOD1 ALS gene therapy program on track for development candidate selection by end of year Conference call at 4:30 p.m. ET today LEXINGTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene... Read More

CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc . (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating results after market close on Monday, November 6, 2023. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and... Read More

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the Chardan 7th Annual Genetic Medicines Conference in New York, NY, on October 2, 2023, at 5:30 p.m. ET. A webcast of the presentation may... Read More

CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with three newly-hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’... Read More

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following investor conferences: Wells Fargo Health Care Conference, Everett, MA – Fireside chat, September 6, 2023, 9:30 a.m. ET Baird Global Healthcare Conference, New York, NY –... Read More

CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into an employment agreement with Beth Shafer, Ph.D., M.A., M.Phil. that, among other things, provides for the grant to Dr. Shafer of a non-qualified stock option and restricted stock units as an inducement material to Dr.... Read More

CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO). Shafer is a seasoned healthcare executive with more than 15 years of experience in corporate and business development at prominent... Read More

Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio Executed license agreement with Sangamo for prion disease treatment Presented validating preclinical results including increased brain transduction of IV-administered TRACER™ capsids across multiple non-human primate species at ASGCT 2023 Conference call at 8:30 a.m. ET today CAMBRIDGE, Mass., Aug. 03, 2023... Read More

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Scientific Officer Todd Carter, Ph.D., and Chief Financial Officer Peter Pfreundschuh will participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023, at... Read More

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report second quarter 2023 financial and operating results before the market opens on Thursday, August 3, 2023. Subsequently, the Company will host a conference call and webcast at 8:30 a.m. ET to review its... Read More

CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with Jacquelyn Fahey Sandell and another newly hired employee that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements... Read More

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (CLO). Fahey Sandell brings more than 25 years of legal experience spanning in-house roles at multiple biotechnology and pharmaceutical companies. She most... Read More

CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3:30 p.m. ET. A webcast of the presentation may be accessed from the Investors section of... Read More

CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, presented data today validating the ability of novel capsids generated through its TRACER™ capsid discovery platform to consistently demonstrate desirable features such as improved blood-brain barrier penetration and increased transgene... Read More

Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet Alzheimer’s disease franchise advances: selected lead candidate for anti-tau antibody program; IND submission on track for first half of 2024; launched tau knock-down gene therapy program Data accepted for presentation at ASGCT 2023 validate blood-brain barrier... Read More

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of George Scangos, Ph.D., to its Board of Directors. Scangos has decades of experience building and leading biopharmaceutical companies, having previously served as CEO of Exelixis, Inc.; Biogen, Inc.; and... Read More

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced seven data presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26 th Annual Meeting, taking place May 16-20, 2023, in Los Angeles. Accepted abstracts and the full preliminary program are available... Read More

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report first quarter 2023 financial and operating results before the market opens on Tuesday, May 9, 2023. Subsequently, the Company will host a conference call and webcast at 8:30 a.m. ET to review its financial and... Read More

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today presented new data from its anti-tau antibody program for Alzheimer’s disease (AD) and from its GBA1 gene therapy program for Parkinson’s disease (PD) and other GBA1-mediated diseases at the AD/PD™ Conference in Gothenburg, Sweden.... Read More

Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACER™ novel capsid platform through transactions with Pfizer and Novartis Partnering momentum continues into 2023 with $175 million payment associated with Neurocrine Biosciences strategic collaboration followed by $25 million payment triggered by Novartis capsid license option exercise Development candidate... Read More

Options exercised on two targets; Voyager eligible to receive associated development, regulatory, and commercial milestones, plus tiered royalties With option exercise, potential to expand agreement to include capsids for up to two additional targets extends for next 18 months CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through... Read More

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report fourth quarter and full year 2023 financial and operating results before the market opens on Tuesday, March 7, 2023. Subsequently, the Company will host a live conference call and webcast at 8:30 a.m. ET to... Read More

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following investor conferences: SVB Securities Global Biopharma Conference (Virtual) – Company presentation, February 16, 2023, 1:40 p.m. ET Cowen 43rd Annual Health Care Conference,... Read More

CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) - - Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with two newly hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’... Read More

Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-sharing in the U.S. for the GBA1 program following Phase 1 readout Neurocrine to receive worldwide rights to Voyager’s GBA1 gene... Read More

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 10:30 a.m. PT / 1:30 p.m. ET. A webcast of the presentation may be... Read More